Improving Patient Access for Gene and Cell Therapies

Please join us for the final session of PGTME's 6th Annual Lunchtime Lecture Series! This talk, presented by Dr. Andrew Lo, will delve into the economics of rare disease and discuss strategies for improving patient access to cell and gene therapies.

Andrew W. Lo is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, director of MIT’s Laboratory for Financial Engineering, principal investigator at MIT's Computer Science and Artificial Intelligence Laboratory, and an affiliated faculty of the Department of Electrical Engineering and Computer Science. His healthcare-related research interests include: new financial engineering tools and business models for drug and device development and healthcare delivery; statistical methods for incorporating patient preferences into the drug approval process; predicting clinical trial outcomes via machine learning techniques; and novel reimbursement models for creating a robust gene and cell therapy ecosystem. He is a co-founder and director of BridgeBio Pharma and Uncommon Cures; a director of Annual Reviews, n-Lorem Foundation, and Vesalius Therapeutics; a co-founder and chairman of QLS Advisors; a co-founder of Quantile Health; and an advisor to several biotech companies.